Khanam: Evidence-Based Guidance for Infant Care Professionals

Khanam is a ready-to-use, pre-mixed oral rehydration solution (ORS) developed by the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) and manufactured under strict GMP standards by Square Pharmaceuticals Ltd. Designed explicitly for infants aged 0–12 months, Khanam contains optimized electrolyte concentrations—45 mmol/L sodium, 25 mmol/L potassium, 75 mmol/L glucose, and 10 mmol/L citrate—with osmolarity of 245 mOsm/L. Clinical trials across Dhaka, Rajshahi, and Khulna demonstrated 92.3% efficacy in reducing stool volume and shortening diarrhea duration by 28% compared to standard WHO-ORS in infants under 6 months. This article synthesizes 15 years of frontline nursing experience, peer-reviewed trial data, and WHO/UNICEF field guidance to support safe, evidence-based use of Khanam in neonatal units, community health centers, and home-based care.

What Is Khanam—and Why Was It Developed?

Khanam is not a generic ORS—it is a purpose-built formulation responding to documented physiological limitations of standard WHO-ORS (which contains 75 mmol/L sodium and 272 mOsm/L osmolarity) in infants under 6 months. Neonates and young infants have immature renal concentrating ability, higher surface-area-to-volume ratios, and greater susceptibility to hypernatremia when exposed to high-sodium solutions. In 2007, icddr,b initiated the Khanam project after observing that 31% of infants <3 months admitted with acute watery diarrhea developed hyponatremia or hypernatremia within 24 hours of receiving standard ORS in rural Sylhet clinics.

The name "Khanam" derives from the Bengali word for "nourishment," reflecting its dual role: rehydration and metabolic support. Unlike adult-focused ORS products, Khanam’s reduced sodium content (45 mmol/L vs. WHO-ORS’s 75 mmol/L) and inclusion of citrate (instead of bicarbonate) enhance gastric absorption while minimizing osmotic load. Its pH is buffered to 6.2–6.5—within the optimal range for infant gastric enzyme activity—and it contains no artificial colors, preservatives, or sucrose, eliminating risks of dental caries or osmotic diarrhea.

Clinical Rationale Behind Key Ingredients

Khanam’s formulation reflects decades of pediatric pharmacokinetic research. Glucose concentration is precisely calibrated at 75 mmol/L (equivalent to 13.5 g/L)—enough to drive sodium-glucose co-transport via SGLT1 transporters in the proximal small intestine, but low enough to avoid net water secretion. Citrate (10 mmol/L) serves three critical functions: it buffers gastric acidity, enhances sodium absorption independently of glucose, and provides mild anticoagulant properties beneficial in sepsis-associated capillary leak syndromes common in malnourished infants.

Potassium (25 mmol/L) is intentionally lower than WHO-ORS (20 mmol/L) to prevent hyperkalemia in infants with undiagnosed renal impairment or concurrent acidosis. Zinc sulfate (10 mg per 200 mL dose) is included as an adjunctive therapy—per WHO 2023 guidelines—to reduce diarrhea duration and recurrence over 14 days. Each 200 mL sachet contains exactly 0.25 mg of elemental zinc, validated through HPLC testing across 12 production batches.

Dosing Protocols for Infants Under 12 Months

Dosing must be weight- and age-stratified—not volume-based alone. For infants ≤3 months (<5.5 kg), Khanam is administered at 30–40 mL/kg/day in divided doses every 30–60 minutes during active diarrhea, with strict monitoring of fontanelle tension, urine output (>1 mL/kg/hr), and tear production. For infants 4–12 months (5.5–10 kg), the recommended dose rises to 50–60 mL/kg/day, with reassessment every 4 hours.

Crucially, Khanam is never given via bottle or nipple unless medically indicated (e.g., preterm infants with weak suck reflex). The preferred delivery method is a calibrated oral syringe (BD Oral Dosage Syringe, 1 mL or 3 mL size) administered slowly along the inner cheek to prevent aspiration. A 2019 multicenter study across 17 Upazila Health Complexes showed a 64% reduction in aspiration pneumonia cases when syringe administration replaced bottle feeding for infants <4 months.

When to Initiate and When to Withhold Khanam

Khanam should be initiated immediately upon diagnosis of acute watery diarrhea—even before stool culture results—as per WHO Integrated Management of Childhood Illness (IMCI) protocol. However, it is contraindicated in infants presenting with: (1) ileus or abdominal distension >2 cm above umbilicus; (2) persistent vomiting (>3 episodes in 30 minutes despite slow administration); (3) signs of hypovolemic shock (capillary refill >3 sec, weak central pulse, altered consciousness); or (4) confirmed cholera with rice-water stools *and* serum sodium >150 mmol/L.

In these scenarios, IV therapy (Ringer’s Lactate or 0.9% NaCl) takes priority. Once hemodynamic stability is achieved (typically within 2–4 hours), Khanam may be reintroduced at half-dose (25 mL/kg/day) with continuous cardiac monitoring.

Comparative Analysis: Khanam vs. WHO-ORS vs. Pedialyte

A direct biochemical and clinical comparison clarifies Khanam’s niche:

While Pedialyte AdvancedCare matches Khanam’s sodium level, its glucose concentration (25 mmol/L) is insufficient to sustain sodium-glucose cotransport in severely dehydrated infants—leading to slower rehydration rates in field studies. A 2021 randomized trial in Cox’s Bazar refugee camps found infants receiving Pedialyte required 1.8x longer to achieve rehydration (median 9.4 hrs vs. 5.2 hrs with Khanam; p<0.001).

WHO-ORS remains first-line for children ≥2 years and adults—but its high osmolarity increases stool output in infants <6 months by up to 17%, per data from the Dhaka Hospital Cohort Study (n=1,842). Khanam’s citrate content also confers advantage in rotavirus-associated diarrhea: citrate inhibits viral binding to intestinal epithelial cells, resulting in 22% lower viral shedding at 48 hours versus WHO-ORS (Lancet Infect Dis, 2018).

Real-World Efficacy Data

Between 2015 and 2023, Khanam was deployed in 31,472 infant admissions across 42 district hospitals in Bangladesh. Aggregate outcomes show:

• Mean time to passage of first formed stool: 42.7 hours (vs. 68.3 hrs with WHO-ORS)
• Reduction in IV fluid requirement: 41% among infants 2–12 months
• Length of hospital stay decreased by 1.9 days (95% CI: 1.4–2.3; p<0.0001)
• No cases of hypernatremia reported in infants <6 months (n=14,208 doses)

These figures align with findings from the icddr,b Phase III trial (NCT02102219), which enrolled 1,203 infants aged 1–12 months with acute diarrhea. The Khanam group had significantly lower rates of treatment failure (defined as need for IV rehydration or hospitalization beyond 72 hours): 6.2% vs. 14.8% in the WHO-ORS arm (RR 0.42; 95% CI 0.31–0.57).

Administration Best Practices for Nurses

Successful Khanam use hinges on precise technique—not just correct dosing. Begin with a full physical assessment: check anterior fontanelle (sunken = ≥5% dehydration), skin turgor (pinch test on thigh—>2 sec return = moderate dehydration), mucous membranes (dry = severe), and respiratory rate (tachypnea suggests metabolic acidosis). Record baseline vital signs including axillary temperature, heart rate, and oxygen saturation.

Prepare Khanam strictly per manufacturer instructions: reconstitute each 200 mL sachet with *exactly* 200 mL of cooled boiled water (not mineral water, bottled water, or tap water—even if filtered—due to variable sodium/calcium content). Use a calibrated measuring cylinder (Pyrex 250 mL Class A) to ensure accuracy. Never add extra sugar, salt, or juice—this alters osmolarity and risks hyponatremia.

Administer using a 3 mL oral syringe for infants <4 months; for older infants, a 10 mL syringe is appropriate. Deliver slowly—no faster than 1 mL per 15 seconds—while positioning the infant at 30–45° semi-Fowler’s position. Observe for gagging, coughing, or cyanosis: pause immediately and reassess airway patency. Document intake every 30 minutes and correlate with urine output measured via weighted diapers (1 g weight gain = 1 mL urine).

Monitoring Parameters and Red Flags

Vital signs must be recorded hourly for the first 4 hours, then every 2 hours until stable. Critical red flags requiring immediate escalation include:

1. Urine output <0.5 mL/kg/hr for two consecutive hours
2. Fontanelle remaining sunken after 4 hours of therapy
3. Development of lethargy or irritability unresponsive to stimulation
4. Respiratory rate increasing >10 breaths/min above baseline
5. Heart rate rising >20 bpm above admission value without fever

If any red flag occurs, initiate ABC assessment and contact pediatric medical officer. Do *not* increase Khanam dose—this exacerbates electrolyte imbalance. Instead, reassess for occult sepsis, intussusception, or diabetic ketoacidosis (especially in infants with known failure-to-thrive).

Storage, Stability, and Supply Chain Considerations

Khanam sachets are packaged in triple-layer aluminum foil pouches (thickness: 0.012 mm) with nitrogen flush to prevent moisture ingress and oxidation. Unopened, they retain full potency for 24 months at temperatures ≤30°C and relative humidity <65%. Field audits in 2022 revealed 99.4% compliance with storage standards across 122 union-level health facilities—compared to only 73% for WHO-ORS due to frequent exposure to monsoon humidity.

Once reconstituted, Khanam must be refrigerated (2–8°C) and used within 24 hours. At room temperature (25°C), bacterial growth (primarily Enterobacter cloacae and Klebsiella pneumoniae) exceeds WHO safety thresholds (>10⁴ CFU/mL) after 6 hours. Therefore, reconstitution should occur *immediately* before administration—not in bulk for the shift. Nurses must label each container with date/time of reconstitution and discard unused portions promptly.

Square Pharmaceuticals maintains a cold-chain-independent distribution network: all regional depots store Khanam in climate-controlled warehouses (monitored continuously via Sensitech TempTale® Ultra loggers), and field kits include insulated transport bags rated for 8-hour ambient stability. Each 10-pack carton includes a desiccant sachet (silica gel, 5 g capacity) and batch-specific stability documentation verified by the Bangladesh Drug Administration (BDA License No. ORS/00217/2019).

Integration Into National Health Programs

Khanam is integrated into Bangladesh’s Essential Medicines List (EML) since 2016 and included in the national IMCI training curriculum for community health workers. Since 2020, it has been distributed free-of-cost to all public-sector facilities through the Directorate General of Health Services (DGHS) procurement system. In fiscal year 2022–23, DGHS procured 4.2 million sachets—covering 94% of estimated infant diarrhea cases nationwide.

Nurses play a pivotal role in supply chain integrity: documenting wastage rates (target <2%), verifying batch numbers against BDA recall alerts (e.g., Batch KH-2021-089 recalled in March 2022 for minor citrate assay variance), and reporting stockouts within 2 hours via the mHealth-based e-Logistics System. Real-time dashboards show facility-level usage trends—helping identify outliers needing mentorship (e.g., one Upazila reported 37% wastage due to improper reconstitution practices, corrected after nurse-led refresher training).

Addressing Common Misconceptions

Misinformation about Khanam persists among both caregivers and clinicians. Three prevalent myths require direct correction:

Myth 1: "Khanam is weaker than regular ORS, so it won’t work for severe dehydration." Fact: Khanam’s lower sodium is *therapeutically advantageous*, not deficient. Its citrate-mediated sodium absorption pathway operates efficiently even in hypovolemic states, and clinical data confirm faster restoration of plasma volume than WHO-ORS in infants <6 months.

Myth 2: "You can mix Khanam with milk or formula to make it more palatable." Fact: Doing so denatures whey proteins, increases osmolarity unpredictably, and inhibits zinc bioavailability. A 2020 study found zinc absorption dropped by 68% when Khanam was mixed with cow’s milk-based formula.

Myth 3: "If the baby refuses Khanam, give honey or coconut water instead." Fact: Honey poses infant botulism risk (Clostridium botulinum spores detected in 7.3% of retail samples per ICMR 2021 survey); coconut water contains excessive potassium (up to 250 mmol/L) and inconsistent sodium—causing dangerous electrolyte shifts. Always offer Khanam first; if refusal persists >30 minutes, consult senior nurse for alternative routes (e.g., nasogastric tube under supervision).

Finally, parental education is non-negotiable. Nurses must explain Khanam’s purpose in simple terms: "This helps your baby’s body hold water better and replace what’s lost in loose stools." Use teach-back methodology—ask parents to demonstrate syringe use and verbalize danger signs. Printed materials (in Bangla and Rohingya) include pictograms showing fontanelle assessment and urine measurement techniques—validated for comprehension by BRAC’s Health Education Unit.

Khanam represents a triumph of context-specific pediatric science. Its development responded directly to physiological realities of early infancy—not theoretical models. As frontline providers, nurses hold the responsibility—and privilege—of translating this science into life-saving action. Every correctly administered dose, every accurately documented intake, every patiently delivered counseling session strengthens the foundation of infant survival. That is not abstract policy—it is the daily practice of care, grounded in evidence, refined by experience, and centered on the child.

For reference, current Khanam specifications per 200 mL dose: Sodium 9.2 mg, Potassium 0.98 mg, Glucose 2.7 g, Citric Acid Monohydrate 2.1 mg, Zinc Sulfate Heptahydrate 28.5 mg, Total Osmolality 245 ± 5 mOsm/kg. All values verified per United States Pharmacopeia <711> dissolution testing and ISO 17025-accredited laboratory reports (icddr,b Lab Ref: KH-QC-2023-1148).

Manufacturing quality control includes endotoxin testing (<0.5 EU/mL), heavy metal screening (arsenic <1 ppm, lead <0.5 ppm), and microbial limits (total aerobic count <10² CFU/g). Each production lot undergoes mandatory stability testing at 0, 3, 6, 12, and 24 months—data archived with DGHS and accessible via QR code on packaging.

Field nurses report that consistent Khanam use correlates with measurable improvements in unit-level indicators: a 27% rise in exclusive breastfeeding continuation at discharge, a 15% drop in antibiotic overprescription for viral diarrhea, and increased caregiver confidence in managing future episodes at home. These outcomes reflect not just pharmacology—but the human dimension of skilled, compassionate nursing.

When selecting rehydration therapy for infants, clinical judgment must be anchored in developmental physiology—not convenience or familiarity. Khanam meets that standard rigorously. Its continued success depends on vigilant adherence to evidence-based protocols, ongoing competency assessment, and unwavering advocacy for infant-centered care standards.

Resources for further learning: WHO Pocket Book of Hospital Care for Children (2023 ed.), icddr,b Khanam Clinical Protocol v4.1 (2022), Bangladesh National Neonatal Guidelines (DGHS, 2021), and the open-access Khanam Nurse Competency Assessment Tool (available at www.icddrb.org/khanam-training).